FDA approves Pfizer's first gene therapy for rare inherited bleeding disorder - eviltoast
The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B who meet certain requirements.

The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B who meet certain requirements.

The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S.

The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B who meet certain requirements.

The treatment will be available by prescription to eligible patients this quarter, a Pfizer spokesperson told CNBC. It has a hefty $3.5 million price tag, before insurance and other rebates, the spokesperson added, making it by far one of the most expensive drugs in the U.S.

  • IamtheMorgz@lemmy.worldEnglish
    2·
    8 months ago

    Don’t worry! I’m sure Pfizer hasn’t gotten any of our tax money to develop this drug, so I’m sure it’s just about recovering costs to make a modest profit!